Price
$59.83
Decreased by -3.19%
Dollar volume (20D)
315.70 M
ADR%
3.85
Earnings report date
Apr 23, 2025
Shares float
387.84 M
Shares short
11.47 M [2.96%]
Shares outstanding
392.11 M
Market cap
23.46 B
Beta
1.50
Price/earnings
42.13
20D range
57.52 76.27
50D range
57.52 93.25
200D range
57.52 117.49

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians.

Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes.

The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

It markets its products directly to endocrinologists, physicians, and diabetes educators.

The company was incorporated in 1999 and is headquartered in San Diego, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Feb 6, 25 0.45
Decreased by -10.00%
0.52
Decreased by -13.46%
Oct 24, 24 0.45
Decreased by -10.00%
0.44
Increased by +2.27%
Jul 25, 24 0.43
Increased by +26.47%
0.39
Increased by +10.26%
Apr 25, 24 0.32
Increased by +88.24%
0.27
Increased by +18.52%
Feb 8, 24 0.50
Increased by +47.06%
0.43
Increased by +16.28%
Oct 26, 23 0.50
Increased by +78.57%
0.34
Increased by +47.06%
Jul 27, 23 0.34
Increased by +100.00%
0.23
Increased by +47.83%
Apr 27, 23 0.17
Increased by +112.50%
0.15
Increased by +13.33%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Dec 31, 24 1.11 B
Increased by +7.64%
151.70 M
Decreased by -40.81%
Increased by +13.62%
Decreased by -45.01%
Sep 30, 24 994.20 M
Increased by +1.97%
134.60 M
Increased by +11.52%
Increased by +13.54%
Increased by +9.36%
Jun 30, 24 1.00 B
Increased by +15.26%
143.50 M
Increased by +23.81%
Increased by +14.29%
Increased by +7.42%
Mar 31, 24 921.00 M
Increased by +24.21%
146.40 M
Increased by +201.23%
Increased by +15.90%
Increased by +142.52%
Dec 31, 23 1.03 B
Increased by +26.90%
256.30 M
Increased by +179.19%
Increased by +24.78%
Increased by +120.01%
Sep 30, 23 975.00 M
Increased by +26.69%
120.70 M
Increased by +19.27%
Increased by +12.38%
Decreased by -5.86%
Jun 30, 23 871.30 M
Increased by +25.15%
115.90 M
Increased by +127.70%
Increased by +13.30%
Increased by +81.94%
Mar 31, 23 741.50 M
Increased by +17.92%
48.60 M
Decreased by -50.05%
Increased by +6.55%
Decreased by -57.64%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY